Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study for Ulcerative Colitis

 Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study for Ulcerative Colitis

Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study for Ulcerative Colitis

Shots:

  • The P-III VARSITY study results involves assessing of Entyvio (vedolizumab,IV) vs Humira (adalimumab,SC) in 769 patients with moderate to severely active ulcerative colitis for 52wks.
  • The P-III VARSITY study results: @52wks. clinical remission (31.3% vs 22.5%); mucosal healing (39.7% vs 27.7%); AEs (62.7% vs 69.2%); rate of infection (33.5% vs 43.5%); SAEs (11.0% vs. 13.7%) @14wks. greater clinical response than adalimumab
  • Entyvio (vedolizumab, IV) is a gut-selective biologic targeting alpha4beta7 integrin, inhibiting its binding with MAdCAM-1, indicated to treat UC & CD. Humira (adalimumab) is an anti-TNF drug, is indicated as monothx. or in combination with methotrexate for RA, psoriatic arthritis, ankylosing spondylitis

Click here to read full press release/ article | Ref: Takeda| Image: Booth Design Ideas

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post